CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
21-821

CHEMISTRY REVIEW(S)
NDA 21-821

Tygacil
(tigecycline) for injection

Wyeth Pharmaceuticals

Shrikant N. Pagay
Anti-Infective Drug Products
Table of Contents

Table of Contents ................................................................. 2
Chemistry Review Data Sheet ......................................................... 5
The Executive Summary .............................................................. 9
   I. Recommendations ........................................................................................................... 9
      A. Recommendation and Conclusion on Approvability ........................................... 9
      B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements,
         and/or Risk Management Steps, if Approvable .............................................. 9
   II. Summary of Chemistry Assessments ................................................................. 9
      A. Description of the Drug Product(s) and Drug Substance(s) ......................... 9
      B. Description of How the Drug Product is Intended to be Used ...................... 10
      C. Basis for Approvability or Not-Approval Recommendation ....................... 11
   III. Administrative ........................................................................................................... 11
      A. Reviewer’s Signature ..................................................................................... 11
      B. Endorsement Block ....................................................................................... 11
      C. CC Block ......................................................................................................... 11

Chemistry Assessment ........................................................................ 12
   I. DRUG SUBSTANCE .................................................................................................... 12
      1. Description & Characterization ............................................................................. 12
         a. Description .................................................................................................................. 12
         b. Characterization / Proof Of Structure ......................................................................... 12
      2. Manufacturer ........................................................................................................... 13
      3. Synthesis / Method Of Manufacture ....................................................................... 14
         a. Starting Materials - Specs & Tests ........................................................................... 14
         b. Solvents, Reagents, etc. ............................................................................................ 16

NDA 21-821
Tigacyl
(tigecycline) for Injection
CHEMISTRY REVIEW

c. Flow Chart................................................................................................................. 17
d. Detailed Description................................................................................................. 17

4. Process Controls ..................................................................................................... 20
   a. Reaction Completion / Other In-Process Tests ......................................................... 20
   b. Intermediate Specs & Tests....................................................................................... 21

5. Reference Standard ............................................................................................... 22
   a. Preparation ................................................................................................................ 22
   b. Specifications............................................................................................................. 22

6. Regulatory Specifications / Analytical Methods................................................... 23
   a. Drug Substance Specifications & Tests........................................................................ 24
   b. Purity Profile............................................................................................................. Error! Bookmark not defined.
   c. Microbiology............................................................................................................. 33

7. Container/Closure System For Drug Substance Storage ....................................... 34

8. Drug Substance Stability......................................................................................... 35

II. DRUG PRODUCT ...................................................................................................... 36

1. Components/Composition ...................................................................................... 42

2. Specifications & Methods For Drug Product Ingredients .................................... 42
   a. Active Ingredient(s)................................................................................................. 43
   b. Inactive Ingredients................................................................................................. 43

3. Manufacturer.......................................................................................................... 44

   a. Production Operations............................................................................................. 48
   b. In-Process Controls & Tests..................................................................................... Error! Bookmark not defined.
   c. Reprocessing Operations......................................................................................... 52

5. Regulatory Specifications And Methods For Drug Product ................................ 52
   a. Sampling Procedures................................................................................................. 52
   b. Regulatory Specifications And Methods..................................................................... 54


7. Microbiology........................................................................................................... 58

8. Drug Product Stability ........................................................................................... 58

III. INVESTIGATIONAL FORMULATIONS ................................................................ 66

NDA 21-821
Tigacyl
(tigecycline) for Injection
IV. ENVIRONMENTAL ASSESSMENT ................................................................. 46
V. METHODS VALIDATION .................................................................................. 72
VI. LABELING ..................................................................................................... 72
VII. ESTABLISHMENT INSPECTION ................................................................. 73
VIII. DRAFT DEFICIENCY LETTER ..................................................................... 74
Chemistry Review Data Sheet

1. NDA 21-821

2. REVIEW #: 1

3. REVIEW DATE: 2/11/05

4. REVIEWER: Shrikant N. Pagay

5. PREVIOUS DOCUMENTS:

<table>
<thead>
<tr>
<th>Previous Documents</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td></td>
</tr>
</tbody>
</table>

6. SUBMISSION(S) BEING REVIEWED:

<table>
<thead>
<tr>
<th>Submission(s) Reviewed</th>
<th>Document Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>9/27/04</td>
</tr>
<tr>
<td>Amendment (stability update)</td>
<td>3/10/2005</td>
</tr>
<tr>
<td>Amendment (Response to deficiency comments)</td>
<td>3/18/05</td>
</tr>
<tr>
<td>Amendment (Response to deficiency comments)</td>
<td>5/4/05</td>
</tr>
<tr>
<td>Correspondence (Response to deficiency comments)</td>
<td>5/27/05</td>
</tr>
<tr>
<td>Amendment (Response to label comments)</td>
<td>6/2/05</td>
</tr>
<tr>
<td>Amendment (update)</td>
<td>6/13/05</td>
</tr>
</tbody>
</table>

7. NAME & ADDRESS OF APPLICANT:

   Name: Wyeth Pharmaceuticals
   Address: P. O. Box 8299, Philadelphia, PA 19101-8299
   Representative: Mr. Norris Pyle
   Telephone: (484)- 865- 3218
8. DRUG PRODUCT NAME/CODE/TYPE:
   a) Proprietary Name: Tygacil
   b) Non-Proprietary Name (USAN): Tigecycline
   c) Code Name/# (ONDC only): GAR-936; WAY 156936
   d) Chem. Type/Submission Priority (ONDC only):
      - Chem. Type: 1
      - Submission Priority: P

9. LEGAL BASIS FOR SUBMISSION: 505 (b)

10. PHARMACOL. CATEGORY: Anti-infective

11. DOSAGE FORM: Injectable (lyophilized powder)

12. STRENGTH/POTENCY: 50 mg/vial

13. ROUTE OF ADMINISTRATION: Injectable

14. Rx/OTC DISPENSED: _X__Rx      ___OTC

15. SPOTS (SPECIAL PRODUCTS ON-LINE TRACKING SYSTEM):
    _____SPOTS product – Form Completed
    _X__Not a SPOTS product

16. CHEMICAL NAME, STRUCTURAL FORMULA, MOLECULAR FORMULA, MOLECULAR WEIGHT:

   **Empirical Formula:** C20H30N2O8
   **Molecular Weight:** 585.66
   **Chemical Name:** [4S-(4α,4α,5α,12αα)]-4,7-Bis(dimethylamino)-9-[2-(1,1-dimethylethyl)acetylamino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide.
   **Laboratory Codes:** Tigecycline; GAR-936; WAY-156936; RS 738-6; 898595C.
17. RELATED/SUPPORTING DOCUMENTS:

A. DMFs:

<table>
<thead>
<tr>
<th>DMF #</th>
<th>TYPE</th>
<th>HOLDER</th>
<th>ITEM REFERENCED</th>
<th>CODE</th>
<th>STATUS</th>
<th>DATE REVIEW COMPLETED</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>III (b) (4)</td>
<td>(b) (4)</td>
<td>(b) (4)</td>
<td>3</td>
<td>Adequate</td>
<td>5/12/2004</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III (b) (4)</td>
<td>(b) (4)</td>
<td>(b) (4)</td>
<td>3</td>
<td>Adequate</td>
<td>5/24/2004</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Action codes for DMF Table:
1 – DMF Reviewed.
Other codes indicate why the DMF was not reviewed, as follows:
2 – Type 1 DMF
3 – Reviewed previously and no revision since last review
4 – Sufficient information in application
5 – Authority to reference not granted
6 – DMF not available
7 – Other (explain under “Comments”)

2 Adequate, Inadequate, or N/A (There is enough data in the application, therefore the DMF did not need to be reviewed)
B. Other Documents: NA

<table>
<thead>
<tr>
<th>DOCUMENT</th>
<th>APPLICATION NUMBER</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>IND</td>
<td>56,518</td>
<td>Original &amp; Amendments</td>
</tr>
</tbody>
</table>

18. STATUS:

<table>
<thead>
<tr>
<th>CONSULTS/ CMC RELATED REVIEWS</th>
<th>RECOMMENDATION</th>
<th>DATE</th>
<th>REVIEWER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biometrics</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EES</td>
<td>Acceptable</td>
<td>3/8/05</td>
<td>Office Of Compliance</td>
</tr>
<tr>
<td>Pharm/Tox</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biopharm</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LNC</td>
<td>Acceptable</td>
<td>5/16/05</td>
<td>Consult</td>
</tr>
<tr>
<td>Methods Validation</td>
<td>Satisfactory</td>
<td>5/2/2005</td>
<td>Consult - OPS Laboratory</td>
</tr>
<tr>
<td>OPDRA</td>
<td>Acceptable</td>
<td>3/18/05</td>
<td>Consult</td>
</tr>
<tr>
<td>EA</td>
<td>Acceptable</td>
<td>6/14/05</td>
<td>CMC Review</td>
</tr>
<tr>
<td>Microbiology</td>
<td>Satisfactory</td>
<td>3/23/05</td>
<td>Bryan Riley- consult</td>
</tr>
</tbody>
</table>

19. COMMENTS:

Please note that all italicized portion of Chemistry Assessment Section are reviewer's comments. The remaining information (data, figures and some responses to deficiencies) is directly incorporated from the submission. This does not apply to the Chemistry Review Data Sheet and the Executive Summary Sections.

Regulatory specifications, i.e., specifications agreed upon CMC review, EER, expiration date of the drug substance and shelf life of the drug product, stability study commitments are listed in the Appendix section for quick reference.
The Chemistry Review for NDA 021-821

The Executive Summary

I. Recommendations

A. Recommendation and Conclusion on Approvability

Recommendation to approve NDA 21-821 from CMC consideration.

B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable

NA

II. Summary of Chemistry Assessments

A. Description of the Drug Product(s) and Drug Substance(s)

Drugs Substance

Tigecycline is a tertiary-butyl glycyl substituted analogue of minocycline. Both tigecycline and minocycline are semi-synthetic tetracycline class of drugs. The chemical structure qualifies it as a new molecular entity. It is a broad spectrum antibiotic. The drug substance is an orange colored odorless powder and melts at Tigecycline is However, the proposed drug substance

The synthesis for tigecycline is a

The drug is The drug substance is freely soluble as well as at pH and aqueous solution, and susceptible to oxidation. However, it is stable as solid when placed in the proposed packaging of glass bottles and stored between for at least 18 months. It is poorly absorbed through the gastro-intestinal tract. The manufacturer of the drug substance is
Drug Product
The drug product is a sterile lyophilized powder (50 mg/vial) constituted with normal (0.9%) saline or 5% dextrose as an injectable solution. Tigecycline could not be developed as a tablet or capsule or oral suspension due to poor oral bioavailability. Also, were necessary to manufacture a sterile drug product. Formulation and process development studies were performed to determine the effects of based on the results of these studies, a stable formulation was developed that contains simply the drug substance, The product is manufactured by lyophilization, filling and packaging into vials. Each of these unit operations involves several steps and in-process controls. The process controls include operations. A overage i.e. fill weight for the 50 mg per vial was necessary to account for the losses during withdrawal of the 50 mg from each vial. The lyophilized drug powder in a dry state is stable for up to 18 months when stored at 25°C/.60% RH. The drug is further diluted into IV bags immediately upon constitution of the vial. The drug product is manufactured at Wyeth's Carolina, Puerto Rico facility by B.

B. Description of How the Drug Product is Intended to be Used

The drug product is intended to be used intravenously following infections in complicated skin and skin structure and complicated abdominal infections. Each vial contains 53 mg tigecycline lyophilized powder constituted with 5.3 mL of normal saline or 5% dextrose solution to achieve a final concentration of 10 mg/mL. Thereafter, 5 mL of the reconstituted solution should be immediately withdrawn from the vial and added to a 100 mL IV bag for infusion. For 100 mg dose, transfer 2 reconstituted vials into the IV bag. The maximum concentration of reconstituted solution in the IV bag should not exceed 1 mg/mL. The reconstituted solution should be orange or yellow in color; if it is discolored, e.g., green or black, then, discard the solution. Examine the solution for particulate matter. The reconstituted solution in the IV bag is stable at room temperature for up to 6 hours and in refrigerator for up to 24 hours. The recommended dosage regimen is an initial dose of 100 mg followed by 50 mg every 12 hours. The infusion time is between 30 to 60 minutes.
C. Basis for Approvability or Not-Approval Recommendation

Critical CMC Considerations for the Approval of NDA 21-821

Both the drug substance and drug product are well characterized. The manufacturing processes are well established. The shelf life for both the drug substance and the drug product are based on sufficient stability data for batches stored under long term storage conditions. The in-process and final drug substance and drug product specifications are set with full justification.

III. Administrative

A. Reviewer’s Signature

B. Endorsement Block

ChemistName/Date: Shrikant N. Pagay
ChemistryTeamLeader Name/Date: James Vidra
Project Manager Name/Date: Judit Milstein

C. CC Block
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Shrikant Pagay
6/15/05 10:52:53 AM
CHEMIST

Jim Vidra
6/15/05 11:14:31 AM
CHEMIST

Norman Schmuff
6/15/05 11:25:25 AM
CHEMIST